Halozyme Therapeutics's EBIT per Share for the
three
months ended in Mar. 2026 was $1.51.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $4.24.
During the past 12 months, the average EBIT per Share Growth Rate of Halozyme Therapeutics was 48.40% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 50.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 40.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Halozyme Therapeutics's EBIT per Share or its related term are showing as below:
HALO'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -98.2 Med: 3 Max: 50.4
Current: 50.4
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Halozyme Therapeutics was 50.40% per year. The lowest was -98.20% per year. And the median was 3.00% per year.
HALO's 3-Year EBIT Growth Rate is ranked better than 86.36% of 1173
companies
in the Biotechnology industry
Industry Median: 15.4
vs HALO: 50.40
Halozyme Therapeutics (NAS:HALO) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Halozyme Therapeutics EBIT per Share Related Terms
Halozyme Therapeutics EBIT per Share Historical Data
* Premium members only.
The historical data trend for Halozyme Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.24
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Halozyme Therapeutics (HALO) has a EBIT per Share of $4.24 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Halozyme Therapeutics and its competitors. According to the industry distribution chart, Halozyme Therapeutics ranks #160 out of 1173 companies in the Biotechnology industry, placing it in the top 13.6%.
Is Halozyme Therapeutics' EBIT per Share too high?
Halozyme Therapeutics' current EBIT per Share is $4.24. The Biotechnology industry median EBIT per Share is 15.40. Halozyme Therapeutics' value of $4.24 is 72.5% below this industry median. Based on the distribution chart, Halozyme Therapeutics ranks #160 out of 1173 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Halozyme Therapeutics has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' EBIT per Share compare to KYMR and IBRX?
According to the Biotechnology industry distribution chart, Halozyme Therapeutics ranks #160 out of 1173 companies for EBIT per Share. This places Halozyme Therapeutics in the top 14% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.40. Halozyme Therapeutics' value of $4.24 is 72.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Halozyme Therapeutics's current EBIT per Share of $4.24 is 72.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Halozyme Therapeutics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Halozyme Therapeutics's current EBIT per Share is $4.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Modestly Undervalued. The stock's GF Value™ is $90.98, compared to a current price of $81.56 — trading 10.4% below its estimated fair value. The current EBIT per Share is $4.24 and 72.5% below the Biotechnology industry median of 15.40. Halozyme Therapeutics' overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current EBIT per Share is $4.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Halozyme Therapeutics (HALO) Overvalued in 2026?
Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be undervalued.
The current stock price of $81.56 is trading 10.4% below its estimated GF Value™ of $90.98.
GuruFocus considers Halozyme Therapeutics to be Modestly Undervalued.
Key valuation signals for HALO:
EBIT per Share: $4.24
GF Value™: $90.98 vs. price of $81.56 (10.4% below fair value)
Industry Position: 72.5% below the Biotechnology median (#160 of 1173)
No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
93GF Score
Get the complete analysis for HALO
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HALO has been successfully added to your 
